Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 45 phantom stock units in a recent SEC filing.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., reported a transaction involving phantom stock units.
• The transaction occurred on April 15, 2025.
• Bourla acquired 45 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Following the reported transaction, Bourla directly owns 707,396 shares of Pfizer common stock.
• The price of the phantom stock units was $22.44.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't convey any particular positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units granted to the CEO as part of his compensation package.
• It provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates

Keywords

Pfizer, Albert Bourla, phantom stock units, SEC Form 4, insider trading, executive compensation, PFE, stock ownership